Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Squaric acid dibutyl ester is a synthetic small molecule used topically as an immunomodulator for the treatment of skin conditions such as warts (verruca vulgaris), alopecia areata, and has been investigated for herpes labialis. Its mechanism of action is not fully understood but is believed to involve redirecting the local inflammatory response by inducing allergic contact dermatitis and stimulating T cells and cytokines in the skin. This immune activation helps target abnormal or infected cells at the site of application. The drug has been developed primarily as a compounded topical agent and remains investigational for most indications[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on squaric acid dibutyl ester.